SCHEMBL6775249

SCHEMBL6775249

O=C(Cc1ccncc1)c1ccc(O)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.62
RAB9A P51151 3/20 0.62
PTPN1 P18031 1/20 0.48
L3MBTL1 Q9Y468 3/20 0.47
ALDH1A1 P00352 2/20 0.47
KDM4E B2RXH2 1/20 0.47
ABL1 P00519 1/20 0.47
POLB P06746 1/20 0.47
ALPI P09923 1/20 0.47
GAA P10253 1/20 0.47
ALPG P10696 1/20 0.47
APEX1 P27695 1/20 0.47
CASP3 P42574 1/20 0.47
RECQL P46063 1/20 0.47
BLM P54132 1/20 0.47
CASP7 P55210 1/20 0.47
CASP6 P55212 1/20 0.47
MCL1 Q07820 1/20 0.47
RIN1 Q13671 1/20 0.47
TDP1 Q9NUW8 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6203734 0.88 ALDH1A1 (0.55) NPC1RAB9AL3MBTL1ALDH1A1KDM4E
SCHEMBL1642242 0.86 NPC1 (0.81) NPC1RAB9APTPN1L3MBTL1ALDH1A1
SCHEMBL7433779 0.83 LMNA (0.58) NPC1RAB9AL3MBTL1ALDH1A1KDM4E
SCHEMBL2645324 0.83 LTA4H (0.58) NPC1RAB9APTPN1L3MBTL1ALDH1A1
SCHEMBL2512740 0.83 RAB9A (0.64) NPC1RAB9AL3MBTL1POLBGAA
SCHEMBL4102938 0.83 L3MBTL1 (0.68) NPC1RAB9AL3MBTL1KDM4EMAPT
SCHEMBL1157353 0.82 ALDH1A1 (0.66) L3MBTL1ALDH1A1KDM4EGAATDP1
SCHEMBL6283084 0.81 RAB9A (0.56) NPC1RAB9AL3MBTL1ALDH1A1KDM4E
Hydrochloric Acid SCHEMBL5253545 0.81 LTA4H (0.56) NPC1RAB9APTPN1L3MBTL1ALDH1A1
SCHEMBL6169033 0.81 RAB9A (0.46) NPC1RAB9AL3MBTL1ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160058894-A1 RADIOLABELED PDE10A LIGANDS ABBVIE DEUTSCHLAND (DE) 2016-03-03 US disclosed
US-20160058894-A1 RADIOLABELED PDE10A LIGANDS ABBVIE DEUTSCHLAND (DE) 2016-03-03 US disclosed
US-9138494-B2 Radiolabeled PDE10A ligands ABBVIE INC. (US) 2015-09-22 US disclosed
US-9138494-B2 Radiolabeled PDE10A ligands ABBVIE INC. (US) 2015-09-22 US disclosed
US-6750213-B2 BONE DISORDERS; UROGENITAL SYSTEM DISORDERS; ANTICANCER AGENTS MERCK & CO., INC. 2004-06-15 US disclosed
US-20030225132-A1 Heterocyclic salts such as 3-(3-Hydroxyphenyl)-2-(4-(2-(1-pyrrolidinium)ethoxyphenol)-2,3-dihydro-1,4 -benzoxathiin-6-ol hydrochloride salt, used as estrane agonists, for phrophylaxis of bone disorders DININNO FRANK P (US) 2003-12-04 US disclosed
US-20020165226-A1 Estrogen receptor modulators MERCK & CO., INC. 2002-11-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020165226-A1 Estrogen receptor modulators ESRRA, GPER1, ESRRB NPC1 945/4885RAB9A 3951/4885PTPN1 3532/4885
US-20160058894-A1 RADIOLABELED PDE10A LIGANDS PDE10A, PDE3A, PDE5A NPC1 664/4885RAB9A 124/4885PTPN1 2769/4885
US-20030225132-A1 Heterocyclic salts such as 3-(3-Hydroxyphenyl)-2-(4-(2-(1-pyrrolidinium)ethoxyphenol)-2,3-dihydro-1,4 -benzoxathiin-6-ol hydrochloride salt, used as estrane agonists, for phrophylaxis of bone disorders GPER1, ESR2, ESR1 NPC1 840/4885RAB9A 4442/4885PTPN1 2087/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.